EMERGENCY:Ophthalmic herpes zoster (shingles affecting the eye area and forehead) with visual loss, severe eye redness, or corneal involvement —call040-46324365immediately — 24 hours, 7 days— 24/7
Post-Herpetic Neuralgia in Hyderabad: Burning Pain After Shingles — Treated Early, Treated Right
Expert PHN management with pregabalin or gabapentin titration, amitriptyline or nortriptyline for burning pain and sleep, lidocaine 5% and capsaicin 8% patches for allodynia, intercostal and sympathetic nerve blocks, spinal cord stimulation for refractory cases, and Shingrix vaccine counselling at KIMS Neuroscience, Secunderabad, Hyderabad.
Post-herpetic neuralgia is the persistent neuropathic pain that remains in the area of a previous herpes zoster (shingles) rash beyond 90 days. It is caused by permanent damage to peripheral sensory nerve fibres by the varicella-zoster virus during the acute infection. The pain — burning, stabbing, or electric-shock quality in exactly the dermatomal area of the previous rash — is frequently accompanied by allodynia: severe pain from the lightest clothing contact. In India, shingles vaccination rates are very low and the older population is large and growing. PHN develops in ~50% of people over 60 who get shingles. Prevention is far better than treatment: antivirals within 72 hours of rash onset, and the Shingrix vaccine for all adults over 50.
- What it is
- Persistent dermatomal burning pain >90 days after shingles rash. Permanent nerve damage from VZV reactivation. Allodynia (clothing contact as severe pain) is the most disabling feature.
- India PHN burden
- Shingles incidence 3–5 per 1,000 person-years in India. PHN in ~50% of over-60 shingles patients. Low vaccination rates and large older population make PHN a growing public health problem.
- The 72-hour window
- Starting acyclovir/valacyclovir/famciclovir within 72 hours of rash onset significantly reduces PHN risk and severity. At KIMS, any shingles patient is started on antivirals immediately.
- Hutchinson sign — ophthalmology emergency
- Zoster vesicles on the TIP OF THE NOSE = nasociliary nerve involvement = high risk of direct eye involvement. URGENT ophthalmology review same day. Risk: corneal scarring, uveitis, secondary glaucoma.
- Shingrix vaccine
- Two doses 2–6 months apart — ~90% reduction in shingles AND PHN in people over 50. Can be given even after previous shingles. Available in Hyderabad private vaccination centres. KIMS recommends for all adults over 50.
- Treatment pathway
- Pregabalin 75–600mg/day · Amitriptyline/nortriptyline (burning + sleep) · Lidocaine 5% patch (allodynia) · Capsaicin 8% patch (8–12 weeks/application) · Intercostal nerve block · SCS for refractory.
- Contact KIMS
- 040-44885000 · PHN multimodal assessment · Capsaicin 8% clinic · Ophthalmology liaison for V1 zoster · Emergency: 040-46324365
| Fact | Details |
|---|---|
| Definition | Pain persisting >90 days after shingles rash · Strictly unilateral, dermatomal · Burning + allodynia + stabbing · Develops in ~50% of >60-year-olds with shingles |
| Prevention | Antivirals within 72 hours (acyclovir/valacyclovir/famciclovir) · Shingrix vaccine (2 doses, 90% PHN prevention) · Available in Hyderabad at private vaccination centres |
| Hutchinson sign | Zoster vesicles on the tip of the nose · Nasociliary nerve involvement · High eye involvement risk · URGENT ophthalmology review same day at KIMS |
| First-line treatment | Pregabalin or gabapentin (central sensitisation) · Amitriptyline/nortriptyline (burning + sleep) · Lidocaine 5% patch (allodynia) · Capsaicin 8% patch (clinic, 8–12 weeks) |
| Interventional options | Intercostal/sympathetic nerve blocks (thoracic/ophthalmic PHN) · Capsaicin 8% clinic application · SCS for refractory cases |
| Paracetamol/NSAIDs | INEFFECTIVE for PHN · Neuropathic pain does not respond to anti-inflammatory analgesics · Neuropathic agents are required |
| PHN prognosis | 30–50% resolve within 3 months · Others persist 1–3 years · Severity reduces over time even when not fully resolving · Treatment significantly reduces intensity even without cure |
About This Condition
Post-Herpetic Neuralgia at a Glance
The essential facts that shape how PHN is recognised, prevented, and treated at KIMS — from its origin in herpes zoster nerve damage and its sharply age-related risk, through India-specific prevention gaps, to the antiviral and Shingrix interventions that change the trajectory of the disease.
What it is
Post-herpetic neuralgia (PHN) is the persistent neuropathic pain that remains in the area of a previous herpes zoster (shingles) rash, persisting beyond 90 days after the onset of the rash. It is caused by permanent damage to peripheral sensory nerve fibres (and sometimes dorsal horn neurons) by the varicella-zoster virus during the acute shingles infection. The pain is often described as burning, stabbing, aching, or electric-shock quality, in exactly the area where the shingles rash occurred, and is frequently accompanied by allodynia (pain from normally non-painful stimuli, such as light clothing contact).
How common
PHN develops in approximately 10–18% of people who get shingles, but this rate rises sharply with age: approximately 50% of people over 60 who get shingles develop PHN. In India, where the shingles (zoster) vaccination rate is very low and the older population is large and rapidly growing, PHN is a significant and growing public health problem. Shingles incidence in India is estimated at 3–5 per 1,000 person-years.
Risk factors for developing PHN
Advanced age (the strongest risk factor — the immune system’s ability to suppress viral reactivation declines with age); severe shingles rash; severe pain during the acute shingles phase (prodromal pain and severe rash pain are the best predictors of PHN); immunocompromised state (HIV, diabetes, cancer, immunosuppressive medications); ophthalmic zoster (V1 distribution — forehead, eye, nose).
Prevention is far better than treatment
Antiviral therapy (acyclovir, valacyclovir, or famciclovir) started within 72 hours of shingles rash onset significantly reduces the duration and severity of acute zoster pain AND reduces the risk and severity of post-herpetic neuralgia. At KIMS, any patient with shingles is advised to start antiviral therapy urgently. The zoster vaccine (Shingrix — recombinant zoster vaccine, RZV) reduces shingles incidence by approximately 90% and PHN risk by approximately 90% in people over 50 — the most effective available prevention.
Emergency
040-46324365
Appointment
040-44885000
When the Rash Heals But the Pain Does Not
A 71-year-old retired teacher in Hyderabad developed a painful blistering rash on the left side of his chest and back 6 months ago. The rash was diagnosed as shingles (herpes zoster) and he was given an antiviral tablet. The rash healed within 3 weeks. The pain did not.
Now, 6 months later, he has a continuous burning sensation over his left chest wall and around the left side of his back, in exactly the area where the rash was. The skin feels as if it is constantly on fire. He cannot wear his shirt against that area — even the lightest cloth contact on the skin causes a sharp shooting pain (allodynia). He cannot sleep on his left side. He has stopped going on walks because the exertion makes the burning worse. He has become withdrawn and depressed.
At KIMS, the diagnosis is post-herpetic neuralgia. The distribution — strictly unilateral, dermatomal, exactly matching the previous rash area — is pathognomonic. No imaging or test is required: the diagnosis is clinical. Management begins: pregabalin 75mg twice daily, titrated upward; amitriptyline 10mg at night; lidocaine 5% patch applied daily to the most painful area; and a referral to the KIMS pain psychologist for depression and adjustment.
PHN is one of the most common causes of chronic neuropathic pain in older adults in India — and one of the most undertreated. The combination of inadequate awareness, stigma about neuropathic pain ("the rash has healed, so why does it still hurt"), and the availability of only symptomatic rather than curative treatments means that many PHN patients in India live with severe, debilitating pain for years without appropriate management. At KIMS, the approach is systematic, multi-modal, and does not accept that burning pain after shingles is simply inevitable or untreatable.
Book a Consultation
Speak directly with our PHN specialist team — neurology, pain medicine, interventional procedures, ophthalmology liaison for V1 zoster, and pain psychology coordinated under one roof. No referral required. Monday to Saturday.
040-44885000Ophthalmic zoster emergency: 040-46324365Why PHN Pain Persists — The Neurobiology
During an acute herpes zoster infection, the varicella-zoster virus reactivates from its dormant state in the dorsal root ganglion (where it has been latent since the original chickenpox infection, sometimes decades earlier). The reactivated virus travels along sensory nerve fibres, producing inflammation, demyelination, and in severe cases, death of peripheral sensory neurons. The dorsal horn neurons in the spinal cord may also be damaged by the intense afferent barrage from the inflamed nerve. Post-herpetic neuralgia results from two distinct mechanisms, which produce overlapping but distinct pain qualities.
Peripheral sensitisation
The damaged peripheral sensory nerve fibres fire spontaneously and excessively, producing the burning, aching, and allodynia. This component responds to topical treatments (lidocaine patches, capsaicin) that reduce peripheral afferent activity.
Central sensitisation
The dorsal horn becomes persistently hyperexcitable from the damage during acute zoster. This produces widespread pain sensitivity and allodynia. This component responds to centrally acting medications (pregabalin, gabapentin, TCAs).
Clinical Features of Post-Herpetic Neuralgia
PHN combines burning pain, allodynia, paroxysmal stabbing pains, and a paradoxical numbness in the same dermatomal distribution as the previous shingles rash. Each feature — including the high-risk ophthalmic zoster presentation — is specifically assessed and managed at KIMS.
Burning pain — the dominant symptom
Constant, severe burning sensation in the area of the previous shingles rash. Patients describe it as the skin being on fire, scalded, or held against a hot surface. The burning is present continuously, varying in intensity but never fully absent. The distribution is strictly unilateral and dermatomal — it does not cross the midline.
Allodynia — pain from light touch
The most functionally limiting feature for many PHN patients. Light touch to the affected skin — from clothing, bed sheets, a hand or draught of air — produces severe pain disproportionate to the stimulus. This is called allodynia. It forces patients to leave clothing off the affected area, sleep in specific positions, and avoid social contact that involves physical proximity. In ophthalmic PHN, allodynia of the forehead and scalp may make combing hair, washing the face, or wearing glasses impossible.
Stabbing and shooting pain
Superimposed on the background burning are episodic stabbing, shooting, or electric-shock pains that arrive spontaneously or are triggered by touch. These paroxysmal pains add to the unpredictability and distress of PHN.
Sensory changes — numbness alongside pain
A paradox of PHN: the damaged nerve fibres simultaneously produce pain (from their abnormal activity) and numbness or reduced sensation in the same area. Patients describe the area as both painful and numb — this is deafferentation pain and reflects the loss of normal sensory input alongside the abnormal nociceptive signalling.
Psychological impact — severe and systematically undertreated
Depression, anxiety, sleep disturbance, social withdrawal, and significant reduction in quality of life are present in the majority of PHN patients with severe, prolonged pain. At KIMS, depression and sleep are specifically assessed and treated as part of the PHN management programme — not left for the patient to manage alone.
Ophthalmic herpes zoster — PHN affecting the face and eye
When shingles involves the ophthalmic division of the trigeminal nerve (V1 — forehead, scalp, eyelid, nose, and the eye itself — herpes zoster ophthalmicus or HZO), the risk of PHN is higher than for thoracic zoster. HZO is the most common form of zoster to produce PHN affecting the face. Additionally, the eye itself can be involved: corneal involvement (dendritic keratitis), uveitis, and secondary glaucoma can occur and are ophthalmological emergencies. Any patient with shingles involving the forehead, eyelid, or tip of nose (the Hutchinson sign — zoster vesicles on the tip of the nose indicate nasociliary nerve involvement and high risk of eye involvement) should be assessed by an ophthalmologist urgently alongside their antiviral treatment. At KIMS, HZO patients are referred urgently to the ophthalmology team on the same day as presentation.
High-Risk Presentations at KIMS
Certain shingles presentations carry a significantly higher risk of severe complications, long-term neuropathic pain, and permanent organ damage. At KIMS, these presentations are treated as neurological and ophthalmological emergencies requiring urgent multidisciplinary care.
Ophthalmic herpes zoster — PHN affecting the face and eye
When shingles involves the ophthalmic division of the trigeminal nerve (V1 — forehead, scalp, eyelid, nose, and the eye itself — herpes zoster ophthalmicus or HZO), the risk of post-herpetic neuralgia is significantly higher than for thoracic zoster. HZO is the most common form of zoster to produce PHN affecting the face.
Additionally, the eye itself can become involved. Complications include corneal involvement (dendritic keratitis), uveitis, and secondary glaucoma — all of which are ophthalmological emergencies that can threaten vision if treatment is delayed.
Any patient with shingles involving the forehead, eyelid, or tip of the nose requires urgent ophthalmological assessment alongside antiviral treatment.
Hutchinson Sign — Important Clinical Warning
Zoster vesicles on the tip of the nose (Hutchinson sign) indicate nasociliary nerve involvement and a high risk of direct eye involvement. This finding requires urgent ophthalmology review.
At KIMS, patients with herpes zoster ophthalmicus are referred urgently to the ophthalmology team on the same day as presentation for integrated neurological and eye care management.
Treatment
Preventing PHN — Antivirals Within 72 Hours and the Zoster Vaccine
Prevention is far better than treatment. The trajectory of shingles and PHN is decided in two windows: the 72-hour antiviral window when shingles begins, and the years of eligibility for the recombinant zoster vaccine. KIMS addresses both at every relevant patient encounter.
Early antiviral treatment of shingles — the most impactful preventive measure
Starting acyclovir 800mg 5 times daily, valacyclovir 1,000mg 3 times daily, or famciclovir 500mg 3 times daily within 72 hours of the shingles rash onset significantly reduces the severity of acute pain, duration of the rash, and the risk and severity of PHN. The 72-hour window is critical: treatment started after 72 hours has progressively less benefit. At KIMS, any patient with active shingles is started on antiviral therapy immediately. This is not a condition where a wait-and-see approach is appropriate.
Zoster vaccine — 90% protection
The recombinant zoster vaccine (Shingrix/RZV — two doses 2–6 months apart) reduces shingles incidence by approximately 90% and PHN risk by approximately 90% in people over 50. It is significantly more effective than the older live attenuated zoster vaccine. Shingrix is available in India at private vaccination centres. KIMS strongly recommends zoster vaccination for all adults over 50, and for younger adults who are immunocompromised. People who have already had shingles can and should be vaccinated to prevent recurrence.
Corticosteroids in acute zoster — limited PHN benefit
A short course of oral prednisolone alongside antiviral therapy during acute shingles reduces the severity of acute pain and speeds rash healing, but does not significantly reduce the risk of developing PHN. It is used at KIMS primarily for the acute pain relief benefit in patients with severe acute zoster.
Treatment at KIMS — Systemic First-Line, Topicals for Allodynia, Interventional for Refractory, and Sleep and Psychological Care
Pregabalin, Gabapentin, and TCAs — The Core PHN Pathway
• Pregabalin 75–600mg/day in 2–3 divided doses: alpha-2- delta ligand that reduces calcium channel-mediated neurotransmitter release in sensitised nociceptive pathways. Evidence: approximately 30–45% of patients achieve 50%+ pain reduction. Well-tolerated. Side effects: dizziness, sedation, weight gain, ankle oedema. Start at 75mg twice daily and titrate every 1–2 weeks. KIMS first-line choice for PHN.
• Gabapentin 900–3,600mg/day in 3 divided doses: similar mechanism to pregabalin but requires 3 times daily dosing and has more variable absorption. Similar efficacy. Less expensive in India than pregabalin. Used when cost is a concern.
• Amitriptyline or nortriptyline 10–75mg at night: tricyclic antidepressants that inhibit noradrenaline and serotonin reuptake, enhancing descending pain inhibition. Effective for burning pain and allodynia, and also improve sleep. Side effects: sedation, dry mouth, constipation, urinary retention. In older adults, nortriptyline is preferred (fewer anticholinergic effects). Contraindicated in significant cardiac conduction disease (ECG before starting). KIMS combines this with pregabalin for most PHN patients.
Topical Treatments — Particularly Effective for Allodynia
• Lidocaine 5% patch: Applied daily to the most painful area for up to 12 hours. Reduces peripheral afferent signalling by sodium channel blockade. Particularly effective for the allodynia component of PHN. Minimal systemic absorption. Available in India. Can be cut to size to fit the affected area.
• Capsaicin 8% patch: A high-concentration capsaicin patch applied in clinic by trained staff for 30–60 minutes under local anaesthetic. Depletes substance P from peripheral nociceptors. Effect lasts 8–12 weeks per application. Effective in approximately 30–40% of patients with PHN. Available at KIMS for eligible patients.
• Capsaicin 0.025–0.075% cream: Over-the-counter cream applied 3–4 times daily. Causes initial burning sensation (from capsaicin mechanism) that diminishes over 2–4 weeks. Less effective than the 8% patch but accessible and inexpensive.
Nerve Blocks and Spinal Cord Stimulation
• Intercostal or thoracic nerve blocks: For thoracic PHN, intercostal nerve block with local anaesthetic and steroid provides temporary but meaningful pain relief (typically 4–8 weeks). Repeated at KIMS when clinically beneficial.
• Sympathetic ganglion block: Stellate ganglion block for ophthalmic PHN; coeliac plexus block for upper abdominal PHN — provides prolonged relief in selected patients with significant sympathetically maintained pain component.
• Spinal cord stimulation (SCS): For severe refractory PHN that has failed multiple medical treatments, SCS delivers electrical stimulation to the dorsal column of the spinal cord, modulating the central sensitisation that drives persistent PHN. SCS is an option discussed at KIMS for patients with severe longstanding PHN and is coordinated with the KIMS pain team.
Sleep and Psychological Management — Treated Alongside the Pain, Not After It
Sleep disruption from PHN pain significantly amplifies daytime pain through reduced descending pain inhibition. At KIMS, sleep is specifically addressed: amitriptyline or nortriptyline at night (which address both pain and sleep); melatonin if sleep initiation is the primary problem; CBT for insomnia (CBT-I) for patients with established sleep disorder.
Depression and anxiety screening (PHQ-9, GAD-7) at every KIMS PHN review, with appropriate referral to the KIMS psychologist and treatment with SSRIs (sertraline, escitalopram) when needed. Duloxetine, an SNRI, addresses both depression and neuropathic pain and is useful when both are present.
Related Conditions
Post-Herpetic Neuralgia belongs to the family of headache and pain syndromes evaluated and managed at KIMS Neuroscience:
FAQs
Frequently Asked Questions
Shingles healed. Pain did not. Burning, constant, turning clothing into an instrument of torture. Post-herpetic neuralgia is not a consequence that has to be tolerated indefinitely — it is a treatable neuropathic pain condition with an evidence-based management pathway that most PHN patients in India have never received.
At KIMS Neuroscience, Secunderabad, Hyderabad, PHN is managed with a multi-modal pathway: pregabalin or gabapentin titrated to therapeutic dose; amitriptyline or nortriptyline for burning pain, allodynia, and sleep; lidocaine 5% patch and capsaicin 8% patch for allodynia; nerve blocks for thoracic and ophthalmic PHN; duloxetine for co-morbid depression; spinal cord stimulation for refractory cases. The zoster vaccine (Shingrix) is recommended to every eligible patient to prevent recurrence.
International enquiries: info@kimsneurosciences.com